Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 39,686 shares of the biopharmaceutical company’s stock after selling 63,770 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Catalyst Pharmaceuticals were worth $926,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CPRX. Rothschild Investment LLC increased its position in Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,520 shares during the period. Advisory Services Network LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at $39,000. Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at $40,000. Financial Life Planners purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter worth approximately $42,000. Finally, First Horizon Corp purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth approximately $52,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $31.15 on Tuesday. The company’s 50 day simple moving average is $25.56 and its 200-day simple moving average is $24.07. The stock has a market capitalization of $3.81 billion, a P/E ratio of 18.43, a price-to-earnings-growth ratio of 0.95 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $32.56.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CPRX shares. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Finally, Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.17.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).